Exhaustive characterizations of antisera to the structurally related peptides pancreatic polypeptide (PP), neuropeptide Y (NPY), and peptide YY (PYY) enabled us to establish the developmental pattem of these peptides in rat and mouse pancreas. PYY was the earliest detectable peptide and was present in all early appearing endocrine cell types. NPY appeared later and occurred exclusively in a subpopulation of insulin cells, whereas PP cells arose latest. At the earliest stage studied, all endocrine cells stored PYY. Most of these cells also contained glucagon. Subsequently, the endocrine cells comprised glucagon+PYY ceh and glucagon+PYY+insulin cells. Later, cells storing either only insulin or insulin+PYY appeared. Quantitations of the relative numbers of these cell ' populations during development were consistent with a precursor role of triple-positive (insulin +glucagon+ PYY) cells. Moreover, bromodeoxyutidine (BdU) injections at E15.5 showed that a large percentage of triple-positive cells were in S-phase and therefore were actively dividing, whereas almost no pure insulin cells or insulin+PYY cells synthesized DNA at this time. These results suggest that PYYpositive endocrine cells may represent precursors for mature islet cells. ( J Hisrochem Cyrochem 44:809-817, 19%) 
Introduction
The pancreas contains four endocrine cell types: glucagon (A), insulin (B), somatostatin (D), and pancreatic polypeptide (PP) cells. It develops by fusion of two buds arising from the dorsal and ventral walls of the foregut (Pictet and Rutter, 1972) . At the beginning of formation of the pancreatic buds, glucagon-immunoreactive cells have been observed, later followed by insulin, somatostatin, and PP cells (Fujii, 1979) . During fetal development, endocrine cells containing more than one of the islet hormones have been identified (Alperts et al., 1988; Hashimoto et al., 1988) . Such observations led to the hypothesis that the four islet cell types differentiate from a common multihormonal precursor that co-expresses islet hormones, including glucagon and insulin, during development (Alperts et al., 1988) . Herrera et al. (1991) were unable to confirm the presence of cells containing both glucagon and insu-lin in the fetal mouse pancreas and further reported that the earliest endocrine cells stored immunoreactive PP together with glucagon. Because PP immunoreactivity was also detected in some insulin and somatostatin cells, they suggested that PP production might be a characteristic of pluripotential precursor cells. In contrast, Teitelman and co-workers (1993) demonstrated that all early insulin cells contained glucagon immunoreactivity and ascribed the inability of Herrera et al. to detect double-positive cells to the fixation protocol. Moreover, cells storing both insulin and glucagon immunoreactants have later been observed in several other species (Larsson and Hougaard, 1994; de Krijger et al., 1992; Lukenius et al., 1992) , and co-expression of both hormone mRNAs has been directly demonstrated in the human fetal pancreas (Larsson and Hougaard, 1994) . Teitelman et al. (1993) claimed that the early PP immunoreactivity detected by Herrera et al. (1991) reflected crossreactivity with NPY, a peptide showing striking sequence similarity to PP. Using a PP-specific antiserum, they found true PP cells to appear around birth. Upchurch et al. (1994) recently reported that they were unable to detect neuropeptide Y (NPY) in the developing mouse pancreas. Instead, they found peptide YY ( P W ) to be localized to developing islet cells displaying either of the classical islet hormones. PYY is a third member of the PP family and shares great sequence similarity with PP and NPY. Herrera et al. (1994) recently reported that promoter-targeted expression of diph-theria toxin A-chain resulted in destruction of the corresponding hormone-producing cell types. Targeting of the toxin to insulin or glucagon cells did not result in alterations in nontargeted islet cell types, whereas targeting to PP cells caused a decrease also in insulin and somatostatin cells. These results suggested that expression of PP was important for the development of insulin and somatostatin cells, either through lineage-dependent or paracrine mechanisms (Herrera et al., 1994) . Due to lack of specific antisera to PP, PYY, and NPY, the authors were, however, unable to determine whether the promoter-construct resulted in expression in true PP cells or in PYY or NPY cells.
The conflicting results of these studies demonstrate that immunological crossreactivity of antibodies raised against peptides of the PP family is a major problem when the cellular localization of these peptides is studied. To evaluate the expression pattern of PF' , PYY, and NPY in developing pancreas and the role of PP cells for insulin and somatostatin cell development, an accurate characterization of the specificities of the various antisera is needed. We have undertaken such a characterization and have applied wellcharacterized antisera to analyze the developmental pattern of PP, NPY, and PYY cells in rat and mouse pancreas. Furthermore, in the hope of disclosing a potential precursor cell population, we have evaluated the proliferative ability of islet cell populations using BrdU injections to label cells actively synthesizing DNA.
Materials and Methods
Dot-blots. The specificity of rabbit antisera to human PP (batch # 615-1054B-248-4). bovine PP (batch # 615-R110-146-5) (both kindly donated by Dr. R. E. Chance, Eli Lilly Co., Indianapolis, IN), ratlporcine PYY (Milab; Malmo, Sweden), ratlhuman NPY[1-20] (Milab), and ratlhuman NPY[l-361 (Peninsula Laboratories; Belmont, CA) was tested with a dotblot technique (Larsson, 1981) . Different amoutns (12.5 ng, 50 ng, and 200 ng) of synthetic rat PP, ratlporcine PYY, and ratlhuman NPY peptides (Peninsula Labs) were spotted onto nitrocellulose membranes using a Hybrislot Manifold (BRL; Gaithenburg, MD) and were exposed to paraformaldehyde vapors for 1 hr at 80°C. After pretreatment with 10% normal swine serum, the membranes were stained with the various peptide antisera using peroxidase-conjugated swine anti-rabbit Ig (Dako AIS; Glostrup, Denmark) as secondary antibody and development in diaminobenzidine-Hz02 medium (Larsson, 1988) . The dot-blots were subsequently scanned (8-bit; 256 gray levels) into a MacIntosh IIfx computer and analyzed using the NIH-Image 1.47 software (NIH; Bethesda, MD).
Animals and Tissue Processing. Wistar rats or Balblc mice were mated overnight; noon of the day when the vaginal plug was discovered was considered as Day 0.5 of gestation (E0.5). Pregnant female rats and mice were sacrificed by CO2 asphyxiation and the fetuses were fixed overnight in 4% paraformaldehyde. With embryos older than E16.5, the abdominal cavity was opened before fixation to facilitate penetration of the fixative solution, Rat embryos were examined at 1-day intervals from E11.0 to E20.5 andmurineembryosatE12.5.El4.5, andE16.5. Thepreciseageof 11.0-11.5day embryos was determined by counting somites. Postnatal rats 1 and 13 days of age were similarly immersion-fxed before dissection. Adult rats were intracardially perfused with the fixative, followed by incubation of the pancreatic tissue in the fixative solution. The splenic and duodenal pancreas or, for embryos between 11.5 and 14.5 days, the gastrointestinal region containing the pancreatic primordia, were dissected out, cryoprotected overnight in 30% sucrose, mounted in Tissue-tek, and frozen in n-hexane cooled by liquid nitrogen. The 11-day embryos were processed without dissection.
Brain and proximal colon from adult rats were processed in the same way as the adult pancreas. The brain was transversely sectioned at the level of the optic chiasm.
Bromodeoxyuridine Incorporation. Pregnant rats on Day 15.5 of gestation were injected IP with 3 mg 5-bromo-2'-deoxyuridine and 0.3 mg 5-fluoro-2'-deoxyuridine (Amersham; Poole. UK) per 100 g body weight. After 2 or 24 hr the fetuses were removed and fixed overnight in 4% paraformaldehyde. The pancreata were dissected out and processed as described in the previous section.
Immunocytochemistry. Five-bm cryostat sections were pretreated for 30 min with 10% normal serum from the species donating the secondary antiserum and exposed at 4% overnight to the following antibodies: polyclonal rabbit antisera to PYY, NPY[1-201, NPY(1-361, human CPON (C-terminal peptide of NPY) (Affiniti; Nottingham, UK), human PP or bovine PP, polydonal guinea pig insulin antisera (Dako AIS) or mouse monoclonal antibodies to glucagon (Glu001) (NovoClone; Novo Nordisk, Bagsvaerd, Denmark) or somatostatin (SomOl8) (NovoClone). Subsequently, the site of antigen-antibody reaction was revealed with the following fluorochrome-conjugated secondary antibodies: fluorescein isothiocyanate (HTC)-conjugated swine anti-rabbit Ig (Dako A/S), Texas red-labeled donkey anti-rabbit Ig (Jackson ImmunoResearch Laboratories; West Grove, PA), 7-amino-4-methyl-coumarine-3-acetic acid (AMCA)-conjugated goat antirabbit Ig (Dako AIS), FIX-labeled goat anti-mouse Ig (Dako AIS), Texas red-conjugated goat anti-mouse Ig (Jackson), FIX-labeled sheep anti-guinea pig Ig (SBL; Stockholm, Sweden), and Texas red-labeled goat anti-guinea pig Ig (Jackson). All secondary antibodies were preabsorbed overnight with 20 Pllml normal serum from the species donating the tissue. For most double and triple stainings, combinations of primary antibodies raised in different species were used in conjunction with different fluorochrome-conjugated, species-specific secondary antibodies. To ensure species specificity, the secondary antibodies were preabsorbed overnight at 4°C with 20 pllml normal serum from the species recognized by the other secondary antibodies. Double stainings with primary antibodies from the same species were performed according to the formaldehyde blocking method of Wang and Larsson (1985) . Briefly, sections were stained with one of the primary antibodies followed by a Texas red-labeled secondary antibody, exposed to paraformaldehyde vapors for 4 hr at 8O"C, and stained with the second primary antibody using an FIX-labeled secondary antibody for visualization as described (Wang and Larsson, 1985) .
The BrdU-containing nuclei were visualized using immunoperoxidase labeling. Initially, the tissue sections were pretreated with methanol containing 0.03% H202 to inhibit endogenous peroxidase activity, digested with 0.002% pepsin in 0.2 M HCI for I5 min, and postfixed in 4% paraformaldehyde for 5 min. After incubation in 10% normal goat serum, the sections were exposed for 1 hr to a mixture of BrdU mouse monoclonal antibodies and nuclease (Amersham). The antigen-antibody reaction was revealed using peroxidase-conjugated goat anti-mouse IgG2, and development in diaminobenzidine-HzO2 medium. Subsequently, the sections were stained for insulin, glucagon, and PYY using indirect immunofluorescence with species-specific secondary antibodies conjugated to different fluorochromes.
Specimens were examined both by conventional transillumination and by fluorescent epi-illumination using selective and aligned F I T , Texas red, and AMCA filters, together with a double FITClTexas red filter. In some double-and triple-stained sections, cells containing one, two, or three immunoreactive hormones were counted in random fields of vision using the selective filters (Leitz, x40 objective, x 10 eyepiece equipped with a grid).
To determine the labeling index (LI) of specific islet cell populations, the numbers of insulin-, glucagon-, and PYY-immunoreactive cells containing BrdU-positive nuclei were counted and expressed as a percentage of the total number of nuclei (BrdU-labeled and -unlabeled) scored for this cell population.
Controls included conventional staining controls as well as absorptions
of the primary antibodies with 20-100 pglml of the corresponding or structurally related Synthetic antigens. Furthermore, to prevent nonspecific binding to peptides rich in basic and/or aromatic residues, all antisera were preabsorbed with 1.6 mglml poly-L-lysine (M, 3700: Sigma) (Scopsi et al.. 1986).
Specificity was also verified by staining Hybrislot models (see above) and adult tissues containing endogenous PP (duodenal pancreas), NPY (brain). and PYY (colon mucosa).
Results

Antisera Characterizations
We tested the specificity of five antisera raised against peptides of the PP family: an earlier bleeding of the antiserum against purified bovine PP used by Herrera et al. (1991) . a previously characterized (Larsson et al., 1976) antiserum to purified human PP, an antiserum to synthetic PYY, an antiserum to synthetic NPY(1-201, and an antiserum to synthetic NPY[l-361. The latter corresponds to the antiserum used by Teitelman et al. (1993) . As shown in Table 1 and Figure 1 , all of the peptide antisera bind their corresponding antigens. In addition, the bovine PP antiserum and the NPY[ 1-36] antiserum crossreact with structurally related peptides. In particular, strong crossreactivity with PYY was noted with both antisera. The antisera that by dot-blot testing were found not to crossreact with the structurally related peptides were used for staining proximal colon and brain (at the level of the optic chiasm). In addition, an antiserum against the C-terminal peptide of the NPY (CPON) precursor was tested. This part of the NPY precursor is structurally unrelated to PP and PYY. In the proximal colon, the PYY-specific antiserum detected scattered endocrine-like cells in the mucosa (Figure 2 ). These cells were not detected by the PPspecific nor by the NPY [I-20] or the CPON antiserum. The latter two antisera, however, detected scattered immunoreactive nerve terminals in the mucosa and muscle wall of the colon. In the brain, the NPY[ 1-20] and the CPON antiserum detected many nerve terminals that were present e.g., in the cerebral cortex, suprachiasmatic nucleus, and the area around th'e third ventricle as well as around pial blood vessels. No nerve staining with the PYY-specific or the PP-specific antiserum was found at this level of the brain (Figure 2 ). Similar staining experiments were undertaken with the antisera that crossreacted with related peptides in the dot-blot system. The bovine PP antiserum thus reacted with the colon endocrine-like cells but not with cerebral nerve terminals ( Figure  2 ). The NPY[ 1-36] antiserum stained both colon endocrine-like Table 1 cells and nerve terminals in the cerebral cortex ( Figure 2 ). Stainings of the duodenal pancreas were also undertaken with both the specific and the crossreactive antisera. Peripheral islet cells were stained with both PP antisera, with the PYY antiserum ( Figures  3A-3F ) and with the NPY[1-36] antiserum. The latter antiserum further detected a few centrally placed islet cells that were also strained with the CPON and with the NPY[1-20] antiserum. In addition, the NPY[ 1-20] antiserum detected a few peripheral islet cells that did not stain either with the CPON antiserum or with the NPY[1-36] antiserum preabsorbed against PYY and PP. Absorption of the NPY[l-201 antiserum with NPY did eliminatestaining of the centrally placed islet cells but not that of the peripheral islet cells. Therefore, the staining of peripheral islet cells with the NPY[ 1-20) antiserum must represent unspecific staining. The three non-crossreacting antisera to PYY, CPON, and PP were used in the following section. Poly-L-lysine preabsorption was without effect on staining with any of these antisera. Absorption controls showed that staining with these antisera was eliminated by the corresponding, but not by the heterologous synthetic antigens.
P Y Y and NPY Occur in Dzflerent Subpopulations of Islet Cells in Adult Rat Pancreas
The three peptides, PP, PYY, and NPY, were detected in islet cells of both the splenic and the duodenal part of the adult rat pancreas. The PP cells were more numerous in the duodenal than in the splenic part and occurred at the islet periphery. In both parts of the pancreas, PYY immunoreactivity was localized to peripheral islet cells, the majority of which represented either somatostatin ( Figures 3A-3C ) or PP cells ( Figures 3D-3F ). About half of the somatostatin cells displayed PYY immunoreactivity, whereas most PP cells were positive for PP only. In a few islets, cellular colocalization between PYY and glucagon was observed. whereas no insulin cells in the adult pancreas contained immunoreactive PYY. The CPON antiserum detected immunoreactivity of low intensity in a few centrally placed islet cells. By double immunofluorescence, all CPON-immunoreactive cells were found to co-store insulin ( Figures 3G-31 ). In addition, scattered insular and extrainsular nerve terminals were CPON-positive. As already indicated in the preceding section. the CPON-immunoreactive structures also stained with NPY antisera. Therefore, in addition to PP, both PYY and NPY/ CPON immunoreactants were present in adult rat pancreatic islet cells, PYY in a subpopulation of noninsulin cells and NPYKPON in a subpopulation of insulin cells. 
PYY Is the Most Predominant Hormone of the PP Family in Developing Rat Pancreas
Immunocytochemistry revealed that PYY-containing cells appeared earlier and were more numerous than PP and NPY cells. Thus, PYY cells were detected in the dorsal pancreatic bud even at the earliest stage studied (22 somites, corresponding to *E11.0) and gradually increased in number thereafter. PP cells were absent from both the splenic and duodenal pancreas until E20.5. when the first few immunoreactive cells were observed. NPY cells were detected by E16.5 using the CPON antiserum. Double immunofluorescence for P q and glucagon showed that in 22-somite embryos most PYY cells also contained glucagon, whereas other cells were only PYY-positive. Later, all immunopositive cells contained both hormones ( Figures 4A-4C ). By the 30somite stage, corresponding to *E11.5, a fraction of the PYY+glucagon cells were also insulin-positive. From E14.5 onwards, the fraction of insulin cells containing both glucagon and PYY declined, and cells co-storing insulin and PYY, but not glucagon, as well as insulin single-positive cells, appeared ( Figures 4D-4G and 5A ). From E14.5 to E18.5, the percentage of insulin cells negative for both PYY and glucagon increased dramatically, whereas the insulin + PYY cells had almost disappeared by birth ( Figure 5A ).
Until late fetal development, almost all glucagon cells co-stored PYY. Subsequently, the fraction of glucagon cells devoid of PYY gradually increased ( Figure 5B) .
The earliest somatostatin and PP cells, appearing by E16.5 and E20.5, respectively, also showed PYY immunoreactivity. From birth onwards, the fraction of somatostatin and PP cells containing PYY decreased. In contrast to insulin cells, a small subpopulation of glucagon and a larger subpopulation of somatostatin and PP cells also displayed PYY immunoreactivity in adult rats.
In the late fetal and neonatal rat pancreas, a subpopulation of PYY cells displayed neither insulin nor glucagon immunoreactivity. To assess the existence of cells containing PYY but none of the classical islet hormones, we performed immunofluorescence labeling of PYY in green (FITC) and of all classical islet hormones occurring at the respective stages in red (Texas red) ( Figures 6A-6C ). This demonstrated the presence of several PYY cells that did not stain for any of the classical islet hormones from E16.5 to birth. Cells positive for PYY only were not detected in the adult pancreas.
The few CPON-immunoreactive cells detected from E16.5 were found to be immunopositive for insulin. Glucagon, somatostatin, and PP were not co-localized with CPON in islet cells at any stage of development. The presence of NPY immunoreactivity in insulin cells in the developing and adult pancreas was further confirmed by the NPY [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] antiserum and by the NPY[1-36] antiserum preabsorbed with PYY and PP.
PFI NPk: ana' P Y Y Immunoreactants in Developing Mouse Pancreas
To compare our results in rat with previously published data on mouse pancreas, E12.5. E14.5, and El6.5 of mouse development were studied. PYY-containing cells were numerous at all stages studied, but few cells immunoreactive for CPON were detected by E14.5. Immunopositive PP cells appeared by E16.5, when they outnumbered the CPON-immunoreactive cell population. All PP cellswere also PYY-positive by E16.5 (Figures 6D-6F ). Counts were made in 
Multihormonal Cehs Synthesize DNA
To evaluate the proliferative activity of islet cells, BrdU was injected into pregnant rats on E15.5 to label nuclei synthesizing DNA. Quadruple immunocytochemistry combining immunoperoxidase staining of BrdU with triple immunofluorescence for PYY, insulin, and glucagon demonstrated the presence of BrdU staining in nuclei of several glucagon + insulin+ PYY-positive cells (Figures 6G-6L) .
In three pancreata, the BrdU labeling index (U) of insulincontaining cells was calculated 2 hr after BrdU injections and demonstrated a higher LI of insulin cells co-storing both glucagon and PYY (8.1 f 1.5./0) than of cells containing only insulin (0.0 f 0.0%) or insulin together with PYY (0.2 * 0.3%) ( Table 2) . Similar studies of three pancreata 24 hr after BrdU injection showed a similarly high LI of insulin+glucagon+ PYY-positive cells (8.6 1.0%) and a lower LI for cells positive for insulin and PYY only (0.8 f 0.7%) and insulin only (0.8 * 1.4%). E145 (A-C) and E175 (D-G) . The section shown in A-C was double stained for glucagon (green immunofluorescence; A) and PYY (red immunofluorescence; E) and photographed in single green (A), single red (E), and double exposure (C). Note that all glucagon cells also are PYY-positive. In D-G is shown a section triple immunostained for glucagon (green immunofluorescence, D), insulin (red immunofluorescence, E) and PYY (blue immunofluorescence, F) and photographed by single green (D), red (E), blue (F), and triple (G) exposure. Note that cells storing different combinations of hormones (PYY+insulin+glucagon, PYY+glucagon, PYY+insulin, insulin, glucagon, or PYY) occur at this stage. Examples of triple-immunopositve cells (appearing in white in the triple exposure, G) are indicated by arrows. Bar = 30 pm.
Discussion
To accurately distinguish among the related peptides PP, NPY, and PYY by immunocytochemistry, a number of tissue and model system stainings were used in conjunction with absorption controls.
Antisera previously used for detecting early appearing "BPF'" cells (Herrera et al., 1991) or "NPY" cells (Teitelman et al., 1993) were found to crossreact with PYY. Three highly specific antisera, one to PP, one to PYY, and one directed to CPON, were selected by this approach. Moreover, the results obtained with the CPON antiserum were corroborated by use of PYY+ PP-preabsorbed antiserum to NPY[l-361 and by an antiserum directed to NPY [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
Results obtained with these antisera show that PYY is the earliest detectable and most widespread hormone of the PP family in the developing pancreas of mouse and rat. True CPONimmunoreactive cells appeared later than PYY cells and were fewer in number, while PP cells emerged latest. Upchurch et al. (1994) have also reported early appearance of PYY cells in the mouse pancreas but were unable to detect NPY cells. Using antisera directed to NPY itself as well as to its precursor sequence (CPON), we were, however, able to detect specific NPYKPON immunoreactivity in developing and adult islet cells. In the rat, these cells were further characterized and were found to represent a subset of insulin cells. This agrees with earlier reports of NPY expression in denervated islets of Langerhans and in insulin-secreting cell lines (Waeber et al., 1993; Jamal et al., 1991) . Very recently, Waeber et al. (1995) reported that NPY and CPON immunoreactivity occurred in a subset of human insulin cells. In addition, they found that most glucagon cells also contained NPYICPON. We also detected staining of peripheral islet cells with our NPY [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] antiserum. However, this staining was not seen with PYY+PP-preabsorbed NPY antiserum nor with the CPON antiserum, and could not be eliminated by absorbing the NPY[1-20] antiserum with NPY . Therefore, this staining represents nonspecific binding of the NPY[ 1-20] antiserum to peripheral rat islet cells. In addition, we found that PP cells appeared shortly before birth (E20.5) in the rat, whereas in the mouse pancreas PP cells arose substantially earlier (E16.5). These results contrast to those of Upchurch et al. (19%) and Teitelman et al. (1993) , who were unable to detect mouse PP cells before birth. This disrepancy probably reflects better sensitivity of our staining procedures and antisera. Thus, optimized protocols were previously found to result in earlier detection of PP cells in the developing rat pancreas (cf. Note added in proof in Sundler et al., 1977) . Herrera et al. (1994) recently reported on expression of a mouse PP promoter-growth hormone receptor construct in transgenic mice by E16.5. Using stainings with the BPP antiserum (which by us was found to crossreact with PYY), they found expression of the transgene in about 12% of the BPP (i.e., PYY)immunoreactive cells by E16.5. We found that by E16.5 all true PP cells in the moue were also PYY-positive and constituted about 10% of all PYY cells. This could indicate that the PP promoter-growth hormone reporter construct resulted in cell-specific expression. However, another construct coupling the PP promoter to diphtheria toxin A-chain was found to abolish all BPP immunoreactive (i.e., PYY) cells (Herrera et al., 1994) . Therefore, this toxin construct must also a c t PYY cells that do not contain true PP
In the rat, all endocrine cells observed at the earliest stage studied contained immunoreactive PYY. The majority of these cells were also glucagon-positive. Later, the pancreatic epithelium contained cells co-storing PYY+glucagon or PYY+ glucagon + insulin. This may indicate that PYY is the earliest expressed pancreatic hormone.
The presence of cells co-storing insulin and glucagon in the developing mammalian pancreas is agreed on by virtually all reports (Larsson and Hougaard, 1994; Upchurch et al., 1994; Teitelman et al., 1993; de Krijger et al., 1992; Lukenius et al., 1992; Alperts et al., 1988; Hashimoto et al., 1988) , except for the paper by Herrera et al. (1991) , who may have used an inappropriate fixation procedure (cf. Teitelman et al., 1993) . With time, insulin cells devoid of glucagon immunoreactivity appeared. Some of these cells also co-stored PYY, whereas others were positive for insulin only. Quantitations showed that, commensurate with the drop in insulin+glu-cagon+PYY triple-positive cells, there was a transient increase in insulin+PYY double-positive cells as well as a substantial increase in cells storing only insulin. At this stage, the majority of glucagon cells were still PYY-positive and only later during development did pure glucagon cells appear. Moreover, the earliest appearing somatostatin and PP cells were also immunoreactive for P W The increase in total endocrine cell numbers that occurs during pancreatic growth and differentiation is substantial (Herrera et al., 1991) . Any precursor cell to mature islet cells should therefore be capable of proliferating. Therefore, if pancreatic islet cells develop over multihormonal stages as suggested (Upchurch et al., 1994 ; Alperts et al., 1988) , one should expect intense proliferative activity of the presumptive multihormonal precursor cells. Previous data (de Krijger et al., 1992) have indicated that human fetal islet cells are unable CO synthesize DNA in vitro. Using in vivo injections of BrdU we were, however, able to document that rat PYY cells co-storing glucagon and insulin could synthesize DNA. The majority of BrdU is taken up and incorporated into DNA by 1 hr after injection (Boswald et al., 1990) . Two hours after injec-tion, quadruple immunocytochemical staining revealed that about 8% of the triple-positive PYY+glucagon+insulin cells had been in S-phase at the time of injection. Interestingly, virtually no insulin or insulin+PYY cells were synthesizing DNA. A similar pattern was detected 24 hr after BrdU injection with only a nonsignificant increase in the LI of insulin-and insulin + PYY-positive cells.
Previously, the average cell cycle time for fetal insulin cells has been estimated at 14.9 hr (Swenne, 1982) . If this estimate equals the generation time for the pancreatic cells in our study, one must assume that the incorporation of BrdU has been followed by mitosis during the following 24 hr. In that case, the similar LI of PYY+ glucagon + insulin triple-positive cells detected 2 and 24 hr after BrdU injection must be caused by a parallel increase in the number of BrdU-negative, triple-positive cells in this period. Alternatively, the daughter cells may have differentiated to other endocrine cell types expressing only one or two ofthe hormones. However, in the timespan studied, a role as precursors to insulin-or insulin+ PYYpositive cells could not be documented with significant certainty. In conclusion, these data show that the triple-positive cells are highly active in DNA synthesis and therefore may constitute precursors to other islet cell types.
